臨床婦人科産科61巻10号

2007年10月発行

今月の臨床 ここまできた分子標的治療 分子標的治療の臨床応用

2．子宮体癌

著者： 加藤聖子¹

所属機関： ¹九州大学生体防御医学研究所ゲノム創薬・治療学分野

ページ範囲：P.1257 - P.1261

はじめに
　子宮体癌は最近増加している癌の1つである．1970年代には，子宮がんの約10％であったが，2002年には47％となっている．
　最近の分子生物学手法の進歩に伴い，癌は遺伝子の病気であることが知られている．子宮体癌においても，その発生に関与する遺伝子・シグナル伝達系の報告が蓄積され，発生機構が明らかになりつつあり，分子標的薬の適応となる疾患の1つであると考えられる．

参考文献

1）井上正樹 : 子宮体部癌発生の分子機構─その前癌病変の多様性．症例から学ぶ婦人科腫瘍学入門．pp89─101，永井書店，2006

2）Ryon AJ, Susil B, Jobling TW, et al : Endometrial cancer. Cell Tissue Res 322 : 53─61, 2005

3）Niederacher D, An HX, Cho YJ, et al : Mutations and amplification of oncogense in endometrial cancer. Oncology 56 : 59─65, 1999

4）Safari B, Jones LA, el─Naggar A, et al : Amplification and overexpression of HER─2／neu（c─erbB2）in endometrial cancers : correlation with overall survival. Cancer Res 55 : 5693─5698, 1995

5）Enomoto T, Inoue M, Peratori AO, et al : K─ras activation in premalignant and malignant epithelial lesions of the human Uterus. Cancer Res 51 : 5308─5314, 1991

6）Sasaki H, Nishii H, Takahashi H, et al : Mutation of the Ki─ras proto oncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53 : 1906─1910, 1993

7）Fukuchi T, Sakamoto M, Tsuda H, et al : Beta─catenin mutation in carcinoma of the uterine endometrium. Cancer Res 58 : 3526─3528, 1998

8）Katabuchi H, Van Ress B, Lamber AR, et al : Mutations in DNA mismatch repoir genes are not responsible for micro satellite instability in most spuradic endometrial carcinomas. Cancer Res 55 : 5556─5560, 1995

9）Kanaya T, Kyo S, Maida Y, et al : Frequent hypermethylation of MLH1 promoter in normal endometrium of patients. withendometrial cancers. Oncogene 22 : 2352─2360, 2003

10）Risinger JI, Maxwell GL, Berchuck A, et al : Promoter hypermethylation as an epigenetic component in Type. Iand Type II endometrial cancers. Ann NY Acod Sci 983 : 208─212, 2003

11）Risinger JI, Hayes AK, Berchuck A, et al : PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57 : 4736─4738, 1997

12）Tashiro H, Blazes MS, Wu R, et al : Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57 : 3935─3940, 1997

13）Kounelis S, Kapranos N, Kouri E, et al : Immunohistochemical profile of endometrial adenocarcinoma : a study of 61 cases and review of the literature. Mod Pathol 13 : 379─388, 2000

14）Moll UM, Chalas E, Auguste M, et al : Uterine papillary serous carcinoma evolves via a p53─driven pathway. Human Pathol 27 : 1295─1300, 1996

15）Zheng W, Cao P, Zheng M, et al : p53 overexpression and bcl─2 persistence in endometrial carcinoma : comparison of papillary serous and endometrial subtypes. Gynecol Oncol 61 : 167─174, 1996

16）Slomovitz BM, Broaddus RR, Schmandt R, et al : Expression of imatinib mesylate─targeted kinases in endometrial carcinoma. Gynecol Oncol 95 : 32─36, 2004

17）Salvatierra A, Tarrats A, Gomez C, et al : A case of c─kit positive high─grade stromal endometrial sarcoma responding to imatinib mesylate. Gynecol Oncol 101 : 545─547, 2006

18）Kato K, Cox AD, Hisaka MM, et al : Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89 : 6403─6407, 1992

19）Kato K, Ueoka Y, Kato K, et al : Contribution of enhanced transcriptional activation by ER to［12Val］K─Ras. mediated NIH3T3 cell transformation. Oncogene 15 : 3037─3046, 1997

20）Kato K, Horiuchi S, Takahashi A, et al : Contribution of estrogen receptor alpha to oncogenic K─Ras─mediated NIH3T3 cell. transformation and its implication for escape from senescence by modulating the p53 pathway. J Biol Chem 277 : 11217─11224, 2002

21）Suga S, Kato K, Ohgami T, et al : An inhibitory effect on cell proliferation by blockage of the MAPK／estrogen. receptor／MDM2 signal pathway in gynecologic cancer. Gynecol Oncol 105 : 341─350, 2007